ARMP · Armata Pharmaceuticals, Inc. · Investor Relations
$3.52
+0.21 (+6.34%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash and cash equivalents of $24.0 million as of June 30, 2026 will not be sufficient to enable us to complete all necessary development of any potential product candidates and fund our operations for the next 12 months from the date the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Market Cap
$133.67M
Shares
37.18M
Volume · Oct 2
124.48K
Avg daily vol (3M)
213.34K
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-20 | 20th International Symposium on Staphylococci and Staphylococcal Infections (ISSSI 2026) | Event |
| 2026-09-14 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-11-25 | Key Opinion Leader (KOL) Webinar: "Redefining SoC in Complicated Staph. aureus Bacteremia to Unlock a Real Opportunity" | Event |
| 2025-10-22 | IDWeek™ 2025 | Event |
| 2025-09-08 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |